Mrna 1273 covid 19 vaccine

The SARS-CoV-2-specific memory T cell cytokines were measured in 180 participants of the multicenter RECOVAC IR study, who were enrolled at the Erasmus MC Rotterdam² . Further, inclusion and exclusion criteria are reported in Supplemental Fig. 1. The RECOVAC IR study was approved by the Dutch Central Committee on Research Involving Human Subjects (CCMO, NL76215.042.21) and the institutional review board of the Erasmus MC Rotterdam (MEC2020-662), and registered at clinicaltrials.gov (NCT04741386). Written informed consent was obtained from all participants. Four different cohorts were included; cohort A: participants without kidney disease (n = 42; control group, eGFR >45 mL/min/1.73 m²); Cohort B: patients with CKD stage G4/5 (n = 44; eGFR <30 mL/min/1.73m²); cohort C: patients undergoing hemo- or peritoneal dialysis (n = 44); and cohort D: KTR (n = 74). All participants received two doses of the mRNA-1273 COVID-19 vaccine (100 µg; Moderna Biotech Spain, S.L.) with an interval of 28 days² . Whole blood samples were obtained before vaccination (baseline), and at 28 days and 6 months after the second vaccination. The samples were processed within 12 h of the blood draw. For clarity of the study design, we made an infographic providing accessible visual information about the study in Supplemental Fig. 2.